Abstract
Background: A novel pneumonia (COVID-19) spread rapidly throughout worldwide, in December, 2019. Most of the deaths have occurred in severe and critical cases, but information on prognostic risk factors for severely ill patients is incomplete. Further research is urgently needed to guide clinicians, and we therefore prospectively evaluate the clinical outcomes of 114 severely ill patients with COVID-19 for short-term at the Union Hospital in Wuhan, China.Methods: In this single-centered, prospective, and observational study, we enrolled 114 severely ill patients with confirmed COVID-19 from Jan 23, 2020, to February 22, 2020. Epidemiological, demographic, laboratory, treatment, and outcome data were recorded, and the risk factors for poor outcome were analyzed.Results: Among the 114 enrolled patients with a mean age of 63.96 ± 13.41 years, 94 (82.5%) patients were classified as a good outcome group. Common clinical manifestations included fever, cough, and fatigue. Compared with the good outcome group, 20 (17.5%) patients in the poor outcome group more frequently exhibited lymphopenia, and lower levels of albumin, partial arterial oxygen pressure, higher levels of lactate dehydrogenase, creatine kinase, hypersensitive troponin I, C-reactive protein, ferritin, blood urea nitrogen, and D-dimer, as well as markedly higher levels of IL-6 and IL-10. Absolute numbers of T lymphocytes, CD8 + T cells, decreased in almost all the patients and were markedly lower in the poor outcome group than the good outcome group. We also found that traditional Chinese medicine can significantly improve the patient's condition, which is conducive to the transformation from a severe to mild condition. In addition, univariate and multivariate Cox analyses of potential factors for poor outcome patients indicated that cytokine storms and uncontrolled inflammation responses as well as liver, kidney, and cardiac dysfunction are related to the development of a poor outcome.Conclusion: In summary, we reported this single-centered, prospective, and observational study for short-term outcome in severe patients with COVID-19. We found that cytokine storms and uncontrolled inflammation responses as well as liver, kidney, and cardiac dysfunction may play important roles in the final outcome of severely ill patients with COVID-19. Our study will allow clinicians to benefit and rapidly estimate the likelihood of a short-term poor outcome for severely ill patients.
Highlights
A pneumonia caused by a novel coronavirus, severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), spread rapidly throughout worldwide in December 2019 [1]
This single-center, prospective study included 114 severe patients with confirmed COVID-19 pneumonia hospitalized at the Union Hospital in Wuhan, China, which is a hospital designated to treat patients with COVID-19
From January 23, 2020, to February 22, 2020, we continuously enrolled patients diagnosed with COVID19 based on interim guidance provided by the World Health Organization (WHO)
Summary
A pneumonia caused by a novel coronavirus, severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), spread rapidly throughout worldwide in December 2019 [1]. Huang et al described the epidemiological, clinical, laboratory, and radiological characteristics of COVID19, as well as various treatment strategies and outcomes, among 41 patients during the first wave of hospitalizations. They compared clinical characteristics between patients treated in an intensive care unit (ICU) and those treated in non-ICU [2]. Few prospective studies have explored the short-term outcomes of severely ill patients under current medical treatment and the risk factors that affect the shortterm outcomes of severely ill patients, especially pneumonia patients with certain chronic diseases, which accounted for the majority of deaths. Further research is urgently needed to guide clinicians, and we prospectively evaluate the clinical outcomes of 114 severely ill patients with COVID-19 for short-term at the Union Hospital in Wuhan, China
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
